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Antigenic analysis of coxsackievirus A9 (CAV9) was carried out by using a peptide scanning method. Immunogenic regions
in the capsid proteins VP1, VP2, and VP3 were recognized by antibodies in the sera of virus-immunized rabbits. The peptide
sequences were scanned using a 12-amino-acid window and three-residue shift. Three immunogenic regions, located in the
N- and C-terminal parts of VP1 and in the N-terminus of VP3, were identified. Trypsin treatment of the virus, known to cleave
off the C-terminus of VP1 containing a functional RGD motif, completely abolished the reactivity against this region but did
not have any other significant effect on antigenicity. In further studies, it was found that the RGD motif itself was poorly
immunogenic whereas antibody-binding sites were located at both sides of the motif. New antigenic sites emerged after heat
treatment of CAV9 at 56 or 100°C prior to immunization; in particular, loop structures between b strands in VP2 exhibited
increased immunogenicity. New antigenic sites in VP1 and VP3 also appeared after the treatments. In spite of the markedly
altered reactivity in peptide scanning, the virus treated at 56°C elicited high titers of neutralizing antibodies. To reveal
cross-reactive antigenic sites, antisera raised against coxsackievirus B3 and echovirus 11 were also tested. The cross-
reactive antigenic sites were located mainly in the N-terminal parts of VP1 and VP3. © 1998 Academic Press
INTRODUCTION
Coxsackievirus A9 (CAV9), an enterovirus in the Picor-
navirus family, is molecularly more closely related to
coxsackie B viruses (CBVs) than to members of the A
subgroup (Pulli et al., 1995). In contrast to CBVs, CAV9
has a C-terminal extension in the VP1 capsid protein
(Chang et al., 1989, 1992); this extension contains a
functional RGD motif which has been shown to react
with av-integrins during early virus–cell interactions
(Roivainen et al., 1991a, 1994). Removal of the RGD-
containing insert by trypsin (Roivainen et al., 1991a, 1996)
or by mutagenesis (Hughes et al., 1995) does not com-
pletely destroy the infectivity, indicating that CAV9 is able
to utilize alternative pathways in its entry into the host
cell.
While CAV9 exhibits the typical pathogenicity in new-
born mice observed after inoculation of members of the
A subgroup (Hyypia¨ et al., 1993), the disease pattern in
humans is more closely related to CBV infections (Grist
et al., 1978). Clinical CAV9 infections are common (Grist
et al., 1978; Hovi et al., 1996) and there is recent evidence
that CAV9 is one of the enteroviruses which may be
associated with the initiation of a pathogenic process
leading to insulin-dependent (type I) diabetes (Hyo¨ty et
al., 1995; Roivainen et al., 1997).
Although the neutralizing epitopes of polioviruses
have been characterized in a detailed manner (Blondel et
al., 1986; Diamond et al., 1985; Minor et al., 1985, 1986;
Page et al., 1988; Patel et al., 1993; Wiegers et al., 1989,
1990), very little is known about the antigenic sites of
other enteroviruses. In polioviruses the neutralization
sites have been mapped onto the three-dimensional
structure of the virion (Hogle et al., 1985; Page et al.,
1988) which is made up of 60 copies of the capsid
proteins VP1-4. External polypeptides VP1, VP2, and VP3
share an eight-stranded antiparallel b barrel structure
where the neutralization epitopes are mainly located in
the exposed loop structures connecting the b strands
(Page et al., 1988).
Enteroviruses are divided into serotypes on the basis
of their reactivity with a panel of neutralizing polyclonal
antibodies; the molecular basis of the serotype definition
is, however, currently obscure. Due to the principle of
serotype definition and the well-known fact that the three
poliovirus serotypes are needed to induce efficient im-
munity against the disease the antibody response in
enterovirus infections is considered highly type specific.
It is known, however, that heat treatment reveals new
antigens in the virion which exhibit cross-reactivity
among the members of the group (Hummeler and Ham-
parian, 1958). This phenomenon is utilized when broadly
reacting antigens for enterovirus diagnostics are pre-
pared and it is possible that cross-reactive antibody
response also plays a role in clinical enterovirus infec-
tions.
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To understand molecular, pathogenetic, and clinical
properties of CAV9 in more detail, in particular in the light
of virus–cell interactions, we carried out antigenic anal-
ysis of the virus by using the peptide scanning technique
(Geysen et al., 1984, 1987). Antigenic regions in the
capsid proteins VP1, VP2, and VP3, recognized by anti-
bodies in rabbit hyperimmune sera, were determined. In
addition to native CAV9, rabbits were also immunized
with trypsin-cleaved virus which has lost the C-terminal
extension to VP1 and heat-treated CAV9. Cross-reacting
epitopes between CAV9 and other representatives of
enteroviruses were also studied.
MATERIALS AND METHODS
Viruses
For immunization, CAV9 (Griggs strain), coxsackievirus
B3 (CBV3; Nancy), and echovirus 11 (EV11; Gregory), all
obtained from American Type Culture Collection (ATCC),
were propagated in susceptible cell lines and purified by
sucrose gradient centrifugation as described previously
(Abraham and Colonno 1984; Smyth et al., 1993). CAV9
was treated with purified trypsin (Sigma Cat No. T8642; 1
mg/mg of virus protein) according to an earlier described
protocol (Roivainen et al., 1991a): Aliquots of CAV9 were
treated for 1 h at 37°C and the cleavage of VP1 was
confirmed by SDS–PAGE and immunoblotting with type-
specific antiserum. Heat treatment of the purified CAV9
and EV11 was accomplished incubating them at 56 or
100°C for 10 min.
Immunization of rabbits
Purified CAV9 (native, trypsin-treated, or heated at 56
or 100°C), CBV3, and EV11 (heated at 56°C) were used
for immunization. For production of antiserum against
native and trypsin-treated CAV9, sequential three 5- to
20-mg doses of the virus were injected with 3- to 4-week
intervals using the popliteal lymph-node method, includ-
ing the use of Freund’s adjuvant as described previously
(Leinonen, 1985). Rabbit sera against heat-treated CAV9
were obtained by primary subcutaneous immunization of
the animals with 15 mg of the virus in Freund’s complete
adjuvant followed by booster doses of 10 and 5 mg in
incomplete adjuvant 3 and 8 weeks later, respectively.
The serum was collected 2 weeks after the last dose.
Immunization of rabbits with CBV3 and heat-treated EV11
was also carried out by the latter protocol.
Synthetic peptides
Partially overlapping peptides covering the capsid pro-
teins VP2, VP3, and VP1 of CAV9 (Griggs strain; Chang et
al., 1989), corresponding to the order in the viral polypro-
tein, were synthesized on cellulose membranes in 96-
spot format according to the manufacturer’s instructions
(SPOTs, Genosys Inc.). The complete sequence of the
capsid proteins was scanned using a 12-amino-acid win-
dow and three-residue shift. Moreover, the carboxy-ter-
minal residues of VP1 were synthesized on cellulose
membranes as peptides in which one amino acid was
deleted step by step from both sides of the RGD motif
(see Fig. 3).
Epitope mapping
All the following steps were performed at room tem-
perature. The peptide-coupled membranes were incu-
bated overnight with blocking buffer [Tris-buffered saline
(TBS), pH 8.0, containing 0.05% Tween 20 (Fluka), 10% of
103 buffer stock solution (Genosys), and 5% w/v su-
crose]. Blocking buffer was removed and the membranes
were incubated for 30 min with the rabbit serum (1:1000
dilution in blocking buffer). The membranes were
washed 5 3 5 min with TBS containing 0.05% Tween 20
(TBS–Tween) and incubated for 30 min with horseradish
peroxidase-conjugated anti-rabbit immunoglobulins
(DAKO; 1:1500 dilution in blocking buffer). They were
washed again 5 3 5 min with TBS–Tween and finally
incubated for 1 min in ECL detection reagent (Amer-
sham). The chemiluminescence was counted in a 1450
MicroBeta liquid scintillation counter (Wallac) for 1
s/spot. As the synthesized peptides were shifted in three
amino acid steps, the final results were calculated as an
average of four spots where the same three amino acid
motif is present. The results were confirmed by exposing
the membranes on X-ray film (Hyperfilm-MP, Amersham)
for 15 s. Visual impressions of the intensities of the spots
correlated well with the LCPS (luminescense counts per
second) in the diagrams. The membranes were regen-
erated by treatment 5 3 10 min in 8 M urea/1% SDS/0.1%
b-mercaptoethanol followed by 5 3 10 min in 50% etha-
nol/40% water/10% acetic acid. Finally, the membranes
were washed 3 3 5 min with TBS–Tween and stored in
the blocking buffer at 4°C. The membranes were tested
with an antiserum obtained from an unimmunized rabbit
(0-serum) between the analysis of immune sera.
Neutralization tests
Neutralizing antibody titers were determined by a mi-
croneutralization assay. Fourfold antiserum dilutions
(starting from 1:4) were incubated first for 2 h at 36°C and
then overnight at room temperature in microtiter wells
with approximately 100 TCID (tissue culture infectious
dose) of CAV9. A total of 30,000 cells/well of green
monkey kidney cells (GMK; obtained from ATCC) or hu-
man rhabdomyosarcoma cells (RD; ATCC) were added
and the incubation was continued at 36°C. Six days later
the neutralization titer was scored after staining the cells
with crystal violet. The titers are expressed as the high-
est dilution exhibiting complete neutralization.
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RESULTS
Antigenic sites recognized by antisera against native
and trypsin-treated CAV9
To identify B-cell epitopes recognized by the rabbit
immunosystem, the membranes containing the overlap-
ping peptides representing the CAV9 capsid proteins
were first incubated with antisera from two rabbits
(codes 296 and 861) immunized with native virus. The
binding of antibodies to the peptides was quantified by
the chemiluminescence method (Fig. 1). The values ob-
tained by antiserum 861 were almost 10 times higher
than those of antiserum 296. Reactive regions were seen
both in the carboxy-terminal and in the amino-terminal
parts of the VP1 protein. Antiserum 861 recognized C-
terminal amino acids 294-STLNTHGAF-302 and the pre-
ceeding residues 270-PITDTRKDINTVTTV-284, whereas
the RGD motif between these two antigenic regions
reacted weakly with this serum. The amino-terminus of
VP1, especially amino acid regions 1-GDVEEAIER-
ARCTV-14 and 21-GPSNSASVPALTAVETGHTSQ-41, was
also highly reactive. Amino acids 60-SESTVENFLGRS-71
showed also some reactivity. The regions recognized by
the antiserum from rabbit 296 were also located at the
terminal regions of the VP1 polypeptide and mostly over-
lapped with those detected by the 861 antiserum.
There were three major immunogenic regions in VP3, rec-
ognized by antiserum 861, all located at the amino terminal half
of the polypeptide (1-GLPTMNTPGSTQFLTSDDFQS-21, 34-
MNIPGEVKNLMEIAE-48, and 52-VVPVNNVQDTTDQMEM-
FRIPVTINAPLQQQ-81). When compared with the known
three-dimensional structure of coxsackievirus B3 (CBV3;
Muckelbauer et al., 1995), genetically closely related to CAV9
(Chang et al., 1989), amino acids 52–81 form the ‘‘knob’’ and a
loop between b strands B and C. Antiserum 296 showed less
reactivity in the N-terminus of VP3. In VP2, one site (154-
EFTSATQSDQTKVQT-168) located in the ‘‘puff’’ region between
b strands E and F was clearly immunogenic in rabbit 861 but
this region was not recognized by the serum from rabbit 296.
One rabbit was immunized with CAV9 treated with
trypsin which cleaves off only the C-terminus of VP1
containing the RGD motif leaving the other capsid pro-
teins intact (Roivainen et al., 1991a). No C-terminal reac-
tivity was observed in the antiserum obtained (Fig. 2),
whereas two other antigenic sites in the N-terminus of
VP1 (Fig. 1) were recognized also by this antiserum. In
VP3, reactivity against the first 33 amino acids was
clearly observed and the amino acids were separated in
two clusters containing amino acids 1-GLPTMNTPGSTQ-
FLT-15 and 19-FQSPCALPQFDVTPS-33. The antiserum
recognized no immunogenic sites in VP2. All the antisera
which were obtained by immunizing the rabbits with
native or trypsin-treated virus clearly neutralized the vi-
rus (Table 1).
Reactivity of the different sera against the carboxy-
terminus of VP1 was studied further by using peptides
representing distinct parts of this region (Fig. 3). Rabbit
serum 861 recognized most of the peptides with the
exception that the ones containing the RGD motif only
and up to four additional C-terminal residues were not
reactive. Rabbit serum 296 recognized only four peptides
containing amino acids located before and after the RGD
motif and the reactivity disappeared when the arginine
preceeding the RGD motif was deleted. The antiserum
raised against the virus heated at 56°C behaved differ-
ently, exhibiting binding to four peptides where the com-
mon amino acid motif was GDMSTLNTH. No reactivity,
significantly different from the background, was ob-
served with antiserum raised against the virus heat de-
natured at 100°C or trypsin treated.
Heat treatment reveals new antigenic sites in CAV9
Although the C-terminus of VP1 was reactive with the
antiserum from the rabbit immunized with the virus pre-
treated at 56°C, the most antigenic region was located
within the first 14 amino acids and the conserved PAL-
TAVETGHT region (amino acids 29–39) was also immu-
nogenic (Fig. 4). When compared to the native CAV9 as
immunogen, heating revealed a new antigenic site (108-
EMFTYLRFDMEVTFVITSRQD-128) in VP1 representing a
C-terminal part of the a-helix between b strands C and D
and b strand D in the predicted 3D structure. When the
virus was denatured by boiling, the antigenicity in VP1
virtually disappeared, with the exception that a new im-
munogenic region (210-YNTLNNLGHIYVRHV-224), exclu-
sively recognized by the serum obtained from the rabbit
immunized with CAV9 heat denatured at 100°C, ap-
peared in the scan.
In VP3, the antiserum from the rabbit immunized with
the virus treated at 56°C bound to residues 25–54, while
the other rabbit serum (CAV9 heat denatured at 100°C
used as antigen) recognized amino acids 82–105. Heat-
ing of the virus also revealed new antigenic sites in VP2,
where the 56°C antiserum recognized three main anti-
genic regions: 46-EATAEDQPTQPD-57 (the C-terminal
part of the a-helix between b strands A and B), 121-
CLLVVCVPEAEMGGAVVG-138 (a part of the b strand E,
and the N-terminal part of the puff region), and 154-
EFTSATQSDQTK-165 (the middle part of the puff, also
recognized by one of the antisera raised against native
CAV9). The main immunogenic sites recognized by the
100°C antiserum were between amino acid residues
46–57, 82–99, and 205-225.
Cross-reacting antigenic sites in other enteroviruses
CAV9, CBV3, and EV11 are known to be genetically
closely related and they belong to the same molecular
cluster (Hyypia¨ et al., 1997). To identify common immu-
nogenic regions between these three viruses, the mem-
branes containing the CAV9 peptides were incubated
with sera from rabbits immunized with native CBV3 and
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FIG. 1. Reactivity of antisera from rabbits 296 and 861 raised against native CAV9 with peptides representing CAV9 capsid protein VP2, VP3, and
VP1 sequences in the polyprotein. The polypeptide sequences were scanned using a 12-amino-acid window with three amino acid steps. The final
results were calculated as an average of four spots where the three same amino acid motif is present and they are expressed as luminescence
counts per second (LCPS). The amino acid sequences shown represent the reactive regions. All 0-sera tested in this study gave values less than
50 in every measurement point (data not shown).
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FIG. 2. Peptide scanning analysis of a rabbit antiserum raised against trypsin-treated CAV9.
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EV11 treated at 56°C to increase cross-reactivity (Fig. 5).
The CBV3 antiserum reacted poorly in general and there
were only two regions where values exceeding the back-
ground were observed: the amino-terminus of VP1 (1-
GDVEEAIERARCTV-14, exhibiting 50% identity between
CAV9 and CBV3 in the primary amino acid sequences)
and amino acids 37-PGEVKNLMEIAEVDS-51 in VP3
(100% identity).
The antiserum raised against heat-treated EV11 rec-
ognized efficiently multiple regions in the CAV9 cap-
sid. Amino acids 9–38 in VP1 (70% identity between
CAV9 and EV11) represented one cross-reacting site
which extended further from amino acid 45 to 59 (SDT-
MQTRHVKNYHSR; 100% identity). The latter part of the
site was exclusively recognized by this antiserum. A
region from the b strand F to the a-helix between b
strands G1 and G2 in VP1 (168-PSIFWTEGNAPARM-
SIPFISI-188; 95% identity) was also reactive with the
antiserum against heat-treated EV11. In VP3, there was
a broad region recognized by the serum proceeding
from amino acid 4 to 30 (85% identity) and continuing
further from amino acid 34 to 45 (83% identity). In VP2
the antiserum bound to amino acids 43-RDDEA-
TAEDQPTQPD-57 (87% identity; a part of the a-helix
between b strands A and B), which was also recog-
nized by the antiserum against CAV9 treated at 56°C
(Fig. 4). Although the CBV3- and heat-treated EV11
antisera recognized amino acid regions in the CAV9
capsid proteins, they did not contain any antibodies
which could neutralize CAV9 (Table 1).
DISCUSSION
The aim of this study was to characterize antigenic
sites of coxsackievirus A9 which has been a focus of our
research due to its unique molecular characteristics in-
cluding receptor recognition by the RGD motif in the
C-terminal extension to the VP1 capsid polypeptide. In
addition to the native virus, B-cell epitopes in trypsin-
treated and heat-treated viruses were analyzed, and
cross-reacting antigenic sites between different entero-
viruses were studied. Our results show that the main
antigenic sites of CAV9 are located in the C-terminus of
VP1 and in the N-terminal parts of VP1 and VP3.
Virus mutants resistant to neutralization by monoclo-
nal antibodies (reviewed in Minor, 1990; Mateu, 1995;
Usherwood and Nash, 1995) and also synthetic peptides
representing viral sequences (Chow et al., 1985; Dia-
mond et al., 1985) have been used for identification of
antigenic sites of picornaviruses. It is generally thought
that only linear epitopes can be recognized by peptide
scanning techniques and therefore nonlinear neutraliza-
tion epitopes could not be identified. However, structural
studies of antibody–protein complexes have shown that
about 15–22 antigen residues may contact the antibody
FIG. 3. Reactivity of the different antisera with peptides representing
the C-terminal part of VP1. The line indicates reactivity of the serum with
the corresponding peptide. No reactivity, significantly different from the
background, was observed with antiserum raised against trypsin-
treated CAV9 or heat denatured at 100°C.
TABLE 1
Neutralization Titer of Antisera in GMK and RD Cells
Serum
Neutralization titer
GMK RD
Rabbit 296 anti-CAV9
0-serum 64 64
Antiserum 3 3 104 1 3 104
Rabbit 861 anti-CAV9
0-serum 16 8
Antiserum 1 3 106 1 3 106
Rabbit anti-CAV9 (trypsinized)
Antiserum 2 3 106 1 3 106
Rabbit anti-CAV9 (56°C)
0-serum 8 8
Antiserum 3 3 104 3 3 104
Rabbit anti-CAV9 (100°C)
0-serum 8 8
Antiserum 8 8
Rabbit anti-CBV3
0-serum 8 8
Antiserum 8 8
Rabbit anti-EV11 (56°C)
Antiserum 8 8
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FIG. 4. Peptide scanning analysis of antiserum from a rabbit immunized with CAV9 pretreated at 56°C and another animal injected with a virus
treated at 100°C.
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FIG. 5. Cross-reacting antigenic sites in CAV9 capsid proteins recognized by antisera raised against native coxsackievirus B3 or echovirus 11
heated at 56°C.
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(Davies and Padlan, 1990) but as few as 2–6 residues
could contribute most of the energy of binding to anti-
body (Novotny et al., 1989). It has been shown that a
number of anti-protein or anti-virus antibodies recognize
synthetic peptides and it has been suggested that such
peptides mimic only a part of a discontinuous epitope
(Van Regenmortel, 1988, 1992). Therefore, part of the
nonlinear epitopes could also be identified by peptide
scanning. In fact, in studies where antigenic sites of
poliovirus type 3 recognized by human sera were studied
by this technique, all known components of the discon-
tinuous cluster of antigenic regions around the fivefold
axis were identified (Roivainen et al., 1991b). However, a
negative result in the peptide scanning does not neces-
sarily mean that a given region is not involved in the
antibody binding.
In polioviruses, which are the only enteroviruses
where antigenic sites have been studied in molecular
detail to date, neutralizing epitopes are located mainly in
the loops exposed in the three-dimensional structure
(Hogle et al., 1985; Page et al., 1988). According to our
results, some of the antigenic sites of native CAV9 are
located in the corresponding regions as in polioviruses
(antigenic sites 2 and 3) but none of the antigenic re-
gions recognized in CAV9 is in the structures involved in
the formation of antigenic site 1 in polioviruses. These
loops in VP1 (B–C, D–E, and E–F) surround the fivefold
symmetry axis. Also in coxsackie B viruses (molecularly
closely related to CAV9) the B–C loop in VP1 contains a
serotype-specific neutralizing antigenic site (Reimann et
al., 1991). It has been shown that polioviruses lose the
antigenicity of site 1 after cleavage by trypsin (Icenogle
et al., 1986; Roivainen and Hovi, 1988) and trypsin cleav-
age also abolishes the antigenicity of an immunogenic
region in the C-terminus of CAV9 VP1. Although the struc-
tural mechanisms of the loss of antigenicity are different,
there may still be some similarities in vivo since the
viruses are prone to effects of proteolytic enzymes dur-
ing their replication in the gut.
The RGD motif at the C-terminus of VP1 recognizes the
vitronectin receptor on the host-cell surface (Roivainen et
al., 1994). Another picornavirus, foot-and-mouth disease
virus (FMDV), uses also an RGD motif in the attachment
to the cells (Fox et al., 1989). The crystal structure of a
synthetic peptide representing the loop containing the
RGD motif of FMDV complexed with the Fab fragment of
a neutralizing antibody showed that the motif partici-
pates directly in the interaction with the antibody mole-
cule (Verdaguer et al., 1995). When the ability of the CAV9
antisera to recognize the C-terminus of VP1 was ana-
lyzed (Fig. 3), it was seen that the RGD motif itself is not
evidently a sufficient structure for binding of the antibod-
ies. Our results suggest that antibodies bind most
strongly to amino acid residues surrounding the RGD
motif and the motif itself is poorly immunogenic.
The antigenic sites recognized by the rabbit serum
raised against trypsin-treated CAV9, lacking the VP1 C-
terminus, were located in the N-terminal parts of VP1 and
VP3. Although both of these regions are internal in the
three-dimensional structure of CAV9 (D. Stuart, personal
communication), the hyperimmune serum to the trypsin-
treated CAV9 contained a high titer of neutralizing anti-
bodies (Table 1). Polioviruses are thought to exist in two
reversible conformations in solution (Mandel, 1976) as
shown by the observations that antibodies against syn-
thetic peptides representing the buried regions bind to
intact poliovirus particles (Chow et al., 1985; Li et al.,
1994; Roivainen et al., 1993). It has also been shown that
CBV3 titers are significantly reduced in mice immunized
before virus inoculation with a peptide representing the
first 15 N-terminal amino acids of CBV3 VP1 (Huber et al.,
1993). An explanation for the antigenicity of the N-termi-
nal parts of VP1 and VP3 could be that CAV9 can also
exist as two interconvertible forms in solution and in the
second form the N-termini of VP1 and VP3 are external-
ized on the surface of the virus particle.
Cross-reacting regions in CAV9 recognized by antisera
against native CBV3 and EV11 heated at 56°C were
mainly in the N-terminal parts of VP1 and VP3. These
regions contain known cross-reactive antigenic entities
among human enteroviruses: A conserved peptide se-
quence PALTAVETGT, which is included in the wide peak
of the immunogenic domain in the N-terminus of VP1, has
been shown to induce production of widely cross-react-
ing antibodies (Hovi and Roivainen, 1993).
Treatment of native poliovirus (N-antigen) at 56°C is
known to lead to a release of the genomic RNA and the
internal VP4 polypeptide (Maizel et al., 1967). The particle is
converted to a new antigenic form (H-antigen) which mim-
ics the immunological properties of the empty capsids
formed during the infection (Hummeler and Hamparian,
1958; Roizman et al., 1959). Heating of CAV9 prior to immu-
nization revealed new antigenic sites located particularly in
the loops between b strands in VP2. The virus treated at
56°C was able to induce neutralizing antibody response.
However, the ability of CAV9 to stimulate production of
neutralizing antibodies vanished after heat denaturing at
100°C and there were no common antigenic sites when
compared to the native virus. On the other hand, the virus
heated at 56°C shared some immunogenic sites with the
native CAV9: the N- and C-termini of VP1, part of the N-
terminus of VP3, and the puff in VP2 recognized by one of
the rabbit antisera. Although the results represent only
individual rabbits, at least one of these sites may be in-
volved in virus neutralization.
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